Andy Chen
Stock Analyst at Wolfe Research
(4.45)
# 320
Out of 5,120 analysts
44
Total ratings
57.69%
Success rate
24.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Peer Perform | n/a | $65.63 | - | 1 | Jan 7, 2026 | |
| IMVT Immunovant | Upgrades: Outperform | $50 | $26.08 | +91.72% | 3 | Jan 6, 2026 | |
| KYMR Kymera Therapeutics | Downgrades: Peer Perform | n/a | $75.62 | - | 3 | Jan 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $548 | $472.01 | +16.10% | 2 | Jan 6, 2026 | |
| ARGX argenx SE | Downgrades: Peer Perform | n/a | $835.68 | - | 3 | Nov 24, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Peer Perform | n/a | $13.06 | - | 3 | Nov 12, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Peer Perform | n/a | $22.83 | - | 1 | Nov 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $339.11 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $45.28 | - | 2 | Aug 4, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $78.24 | -37.37% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $20.72 | - | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $72.74 | -24.39% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $61 | $15.79 | +286.32% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $50.54 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $49.35 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $34.30 | -41.69% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $18.15 | +4.68% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $102.67 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $24.66 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $489.73 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $33.20 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $57.68 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $83.07 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $51.31 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $21.94 | -22.52% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $153.98 | -72.72% | 1 | Feb 15, 2024 |
Apogee Therapeutics
Jan 7, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $65.63
Upside: -
Immunovant
Jan 6, 2026
Upgrades: Outperform
Price Target: $50
Current: $26.08
Upside: +91.72%
Kymera Therapeutics
Jan 6, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $75.62
Upside: -
Vertex Pharmaceuticals
Jan 6, 2026
Upgrades: Outperform
Price Target: $548
Current: $472.01
Upside: +16.10%
argenx SE
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $835.68
Upside: -
Intellia Therapeutics
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $13.06
Upside: -
Apellis Pharmaceuticals
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $22.83
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $339.11
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $45.28
Upside: -
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $78.24
Upside: -37.37%
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $20.72
Upside: -
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $72.74
Upside: -24.39%
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $15.79
Upside: +286.32%
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $50.54
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $49.35
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $34.30
Upside: -41.69%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $18.15
Upside: +4.68%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $102.67
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $24.66
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $489.73
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $33.20
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $57.68
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $83.07
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $51.31
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $21.94
Upside: -22.52%
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $153.98
Upside: -72.72%